Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Core Insights - Aardvark Therapeutics, Inc. has granted a stock option to a new employee as part of its 2025 Inducement Equity Incentive Plan, which includes 4,881 shares of common stock [1][2] Company Overview - Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics aimed at activating innate homeostatic pathways for metabolic diseases [1][4] - The company is developing treatments specifically for Prader-Willi Syndrome (PWS) and other metabolic diseases, with its lead compound, ARD-101, currently in Phase 3 clinical development for hyperphagia associated with PWS [4] - Aardvark is also working on ARD-201, a fixed-dose combination therapy, and conducting trials to address limitations of existing GLP-1 therapies for obesity and related conditions [4] Stock Option Details - The stock option granted has an exercise price of $10.44, which is the closing price of Aardvark's common stock on the grant date [3] - The option will vest over four years, with 25% vesting on the one-year anniversary of employment and the remainder vesting monthly thereafter, contingent on continued employment [3]